Park of Active Molecules developed a blood substitute

| By | Clinical Trials, Drug Development, R&D
0
1976

PAM-3, a polyhemoglobin blood substitute for military medicine developed by the scientists of the Alliance of Competences “Park of Active Molecules” (PAM) in the Kaluga region, was included in the projects followed by the Ministry of Defence of the Russian Federation. The medicine can become a part of state reserves to be used in case of war, terrorist attacks and disasters, announced the press service of Kaluga region government.

According to the developers, there are no analogs with the properties of polyhemoglobin in the world. The medicine passed Phase 1 of clinical trials. “In case of successful Phase 2 and Phase 3, the technology used for obtaining polyhemoglobin can lead in the very near future to a breakthrough not only in the Russian market but also in the international markets of blood substitutes,” said the press service of the regional government.

The government added that the trials of medicine can be included in the scientific work plan under the state defense order.

PAM-3 is a long-term storage powder, and the standard electrolytes can be used for its dilution and intravenous administration.